173 related articles for article (PubMed ID: 23587922)
1. Potentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine.
Zhou J; Cheung AK; Liu H; Tan Z; Tang X; Kang Y; Du Y; Wang H; Liu L; Chen Z
Mol Ther; 2013 Jul; 21(7):1445-55. PubMed ID: 23587922
[TBL] [Abstract][Full Text] [Related]
2. PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice.
Zhou J; Cheung AK; Tan Z; Wang H; Yu W; Du Y; Kang Y; Lu X; Liu L; Yuen KY; Chen Z
J Clin Invest; 2013 Jun; 123(6):2629-42. PubMed ID: 23635778
[TBL] [Abstract][Full Text] [Related]
3. siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals.
Breton G; Yassine-Diab B; Cohn L; Boulassel MR; Routy JP; Sékaly RP; Steinman RM
J Clin Immunol; 2009 Sep; 29(5):637-45. PubMed ID: 19562472
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines.
Dai B; Xiao L; Bryson PD; Fang J; Wang P
Mol Ther; 2012 Sep; 20(9):1800-9. PubMed ID: 22588271
[TBL] [Abstract][Full Text] [Related]
5. A Δ42PD1 fusion-expressing DNA vaccine elicits enhanced adaptive immune response to HIV-1: the key role of TLR4.
Cheng L; Tang X; He Y; Ju B; Wang H
Virol J; 2022 Nov; 19(1):174. PubMed ID: 36320043
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis.
Cheng L; Tang X; Liu L; Peng J; Nishiura K; Cheung AK; Guo J; Wu X; Tang HY; An M; Zhou J; Cheung KW; Wang H; Guan X; Wu Z; Chen Z
MAbs; 2015; 7(3):620-9. PubMed ID: 25692916
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.
Shin SP; Seo HH; Shin JH; Park HB; Lim DP; Eom HS; Bae YS; Kim IH; Choi K; Lee SJ
Mol Ther; 2013 Mar; 21(3):688-95. PubMed ID: 23337984
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
Song MY; Park SH; Nam HJ; Choi DH; Sung YC
J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
[TBL] [Abstract][Full Text] [Related]
9. Co-immunizing with PD-L1 induces CD8
Guo S; Xiao P; Li B; Wang W; Wang S; Lv T; Xu X; Chen C; Huang L; Li Z; Tang L; Peng L; Wang H
Int Immunopharmacol; 2020 Jul; 84():106516. PubMed ID: 32334387
[TBL] [Abstract][Full Text] [Related]
10. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
11. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
12. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
[TBL] [Abstract][Full Text] [Related]
13. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
Wahid M; Pratoomthai B; Egbuniwe IU; Evans HR; Babaei-Jadidi R; Amartey JO; Erdelyi V; Yacqub-Usman K; Jackson AM; Morris JC; Patel PM; Bates DO
Cancer Immunol Immunother; 2023 Dec; 72(12):4001-4014. PubMed ID: 37973660
[TBL] [Abstract][Full Text] [Related]
14. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
15. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
Kim BJ; Kim BR; Kook YH; Kim BJ
Front Immunol; 2018; 9():643. PubMed ID: 29636755
[TBL] [Abstract][Full Text] [Related]
16. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
[TBL] [Abstract][Full Text] [Related]
17. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
Idoyaga J; Lubkin A; Fiorese C; Lahoud MH; Caminschi I; Huang Y; Rodriguez A; Clausen BE; Park CG; Trumpfheller C; Steinman RM
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2384-9. PubMed ID: 21262813
[TBL] [Abstract][Full Text] [Related]
18. Enhanced humoral and CD8+ T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells.
Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zhang XJ; Zheng YB; Zheng YP; Hong T; He JS
Int Immunopharmacol; 2017 May; 46():62-69. PubMed ID: 28259002
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
20. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
